PMID- 33013389
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and 
      Characteristics.
PG  - 552102
LID - 10.3389/fphar.2020.552102 [doi]
LID - 552102
AB  - BACKGROUND: Due to their efficacy and tolerability, utilization of proton pump 
      inhibitors (PPI) has significantly increased worldwide. Parallel to the clinical 
      benefits, potential long-term side effects have been observed, which, along with 
      increasing medical expenses and potential drug interactions, justifies the 
      analysis of the trends of utilization. OBJECTIVE: The aim of the present study 
      was to show the level, pattern, and characteristics of PPI use. METHODS: We 
      assessed the nationwide use of proton pump inhibitors in ambulatory care based on 
      aggregated utilization data from the National Health Insurance database. The 
      annual PPI utilization was expressed as the number of packages and as number of 
      DDDs per 1,000 inhabitants and per year. For 2018, we estimated PPI exposure as 
      the number of packages and as the number of DDDs per user per year. The annual 
      reimbursement costs of proton pump inhibitors were also calculated. Moreover, 
      three patient-level surveys were carried out in non-gastroenterological inpatient 
      hospital departments to reveal characteristics of proton pump inhibitor use, 
      namely dose, duration, and indication. RESULTS: The PPI utilisation increased 
      from 5867.8 thousand to 7124.9 thousand packages and from 41.9 to 50.4 DDD per 
      1,000 inhabitants and per day between 2014 and 2018. Nationwide data showed that 
      14% of the adult population was exposed to proton pump inhibitors in 2018, while 
      among hospitalized patients, the prevalence of proton pump inhibitor use was 
      between 44.5% and 54.1%. Pantoprazole was the most frequently used active 
      ingredient, both in the nationwide data and in the patient-level surveys. In the 
      patient-level survey in majority of patients (71.5%-80.0%) proton pump inhibitors 
      were prescribed for prophylaxis. Many inpatients (29.4%-36.9%) used 80 mg 
      pantoprazole per day. The average number of PPI packages per user was 6.5 in 2018 
      in the nationwide data. The duration of PPI therapy was typically between 1 and 5 
      years in the patient-level surveys and nearly 20% of the inpatients had been 
      taking proton pump inhibitors for more than 5 years. CONCLUSIONS: Our data 
      suggests that Hungarian patients receive proton pump inhibitors in high doses and 
      for a long time. Use of proton pump inhibitors beyond their recommended 
      indications was also found.
CI  - Copyright (c) 2020 Matuz, Benko, Engi, Schvab, Doro, Viola, Szabo and Soos.
FAU - Matuz, Maria
AU  - Matuz M
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
FAU - Benko, Ria
AU  - Benko R
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
FAU - Engi, Zsofia
AU  - Engi Z
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
FAU - Schvab, Krisztina
AU  - Schvab K
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
FAU - Doro, Peter
AU  - Doro P
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
FAU - Viola, Reka
AU  - Viola R
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
FAU - Szabo, Maria
AU  - Szabo M
AD  - Department of Surgery, Albert Szent-Gyorgyi Health Center, University of Szeged, 
      Szeged, Hungary.
FAU - Soos, Gyongyver
AU  - Soos G
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 
      Szeged, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7506043
OTO - NOTNLM
OT  - nationwide data
OT  - patient-level survey
OT  - proton pump inhibitors
OT  - proton pump inhibitors dose
OT  - proton pump inhibitors exposure
OT  - proton pump inhibitors therapy duration
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
PMCR- 2020/09/08
CRDT- 2020/10/05 06:14
PHST- 2020/04/15 00:00 [received]
PHST- 2020/08/14 00:00 [accepted]
PHST- 2020/10/05 06:14 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
PHST- 2020/09/08 00:00 [pmc-release]
AID - 10.3389/fphar.2020.552102 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Sep 8;11:552102. doi: 10.3389/fphar.2020.552102. 
      eCollection 2020.